2020年11月2-5日
Now Delivered Digitally,
in US Pacific Standard Time (PST)
LOOKING BEYOND ANTIBODIES TO TRANSFORM PROMISING NOVEL MOLECULES INTO NEXT GENERATION MEDICINE
Advance your innovative biologics with cutting-edge engineering, design and conjugates, progress to the clinic and achieve top quality products with analytics and successful workflows.
Introduction Video
作者：伊甸·特纳和汤姆·布劳顿
Conference Producers for Next Generation Protein Therapeutics & Bioconjugates Summit
Interested in speaking opportunities? Or, if you have any questions about the event, please reach out directly:
重新定义你的学习体验
在当前的全球气候下，蛋白质治疗学和生物结合社区比以往任何时候都更重要的是以安全、负责的方式相互联系、制定战略和分享想法。
With our dedication to address the most pressing issues, our Next Generation Protein Therapeutics & Bioconjugates Summit, now taking place November 2-5, 2020, has undergone a timely transformation, moving to an all-digital format and offering attendees the ability to participate in virtual content, exhibits and networking opportunities.
这项全虚拟活动的独特优势
这项全虚拟活动的独特优势
- 可定制的议程，可访问扩展的会话选项
- 方便的会话调度可提高生产效率
- On-demand access to content and topic resources
- 交互式演示/小组讨论，强化学习
- 有针对性的问题解决和解决方案来源
- Broader industry benchmarking and post-event analytics/insights
- 直接接触思想领袖和专家
网络的力量金博宝188app网址
网络的力量金博宝188app网址
谁是谁？
与会者和公司简介提供了对代表团和赞助组织的深入了解
高级搜索功能，可识别机会和潜在合作伙伴
When and How to Connect?
完善的无缝调度工具，用于建立会议tim
DIGITAL CAPABILITIES AND FEATURES
DIGITAL CAPABILITIES AND FEATURES
- 访问虚拟环境
- 观众问答
- Live Polling
- 专家主导的问题解决
- 虚拟网络和合作金博宝188app网址金博宝188备用地址
全面的内容和动态特性
全面的内容和动态特性
- 三0+ Pre-recorded Presentations that will become on-demand at the end of each day
- 超过6小时的现场演讲问答
- 金博宝188app网址与行业同事和同行建立联系
在变革时期，聆听30多位专家的关键蛋白质疗法和生物结合见解，其特点是：
现场演示和问答
Throughout the week there will be live panel discussions and content streamed. Attendees can view by going into the "Live" section of the portal at the designated time listed in US Pacific Standard Time zone (PST). Polling and Q&A will be live through various sessions and sessions will be recorded for viewing at a later time if desired.
KEYNOTE: Immune-empowered Antibodies and Bispecific Molecules for Oncology: Bench to Bedside
KEYNOTE: Immune-empowered Antibodies and Bispecific Molecules for Oncology: Bench to Bedside
Paul Moore，博士，宏基因免疫学和细胞生物学副总裁
KEYNOTE: Cancer Wars: The Rise of Antibody Drug Bioconjugates
KEYNOTE: Cancer Wars: The Rise of Antibody Drug Bioconjugates
Rakesh Dixit, President & CEO, Bionavigen
结合蛋白：缓解清除机制和改变生物分布的合理设计
结合蛋白：缓解清除机制和改变生物分布的合理设计
Mary Bossard, Principal Fellow, Nektar Therapeutics
新型双特异性受体单克隆抗体融合的工程设计及经验教训
新型双特异性受体单克隆抗体融合的工程设计及经验教训
Bernhard Sielaff，首席研究科学家II，Abbvie
XTENylated蛋白酶激活T细胞接合器：XPATS——一种缓解靶向、非肿瘤问题的新形式
XTENylated蛋白酶激活T细胞接合器：XPATS——一种缓解靶向、非肿瘤问题的新形式
Volker Schellenberger, CTO, Amunix
New Technologies To Advance Bispecific Antibodies From Research Into Early or Clinical Development
New Technologies To Advance Bispecific Antibodies From Research Into Early or Clinical Development
Christoph Spiess，基因技术公司抗体工程首席科学家
主旨：大池三桥的ADC概述：基于DXd的ADC的临床前和临床更新
主旨：大池三桥的ADC概述：基于DXd的ADC的临床前和临床更新
长谷川俊，大池三桥高级研究员
KEYNOTE: Update on applications of CrossMab Technology for the Generation of Bispecific Antibodies for Cancer Immunotheray
KEYNOTE: Update on applications of CrossMab Technology for the Generation of Bispecific Antibodies for Cancer Immunotheray
Christian Klein, Head Oncology Programs, Roche Innovation
KEYNOTE: Optimising ADCs Through Choice of Antibody, Site, Linker and Payload
KEYNOTE: Optimising ADCs Through Choice of Antibody, Site, Linker and Payload
Thomas Pillow, Senior Scientist, Genentech
主题：产生和工程抗体的实验和计算方法与药物一样的性质
主题：产生和工程抗体的实验和计算方法与药物一样的性质
Peter Tessier，Albert M Mattocks，密歇根大学药学教授
KEYNOTE: Cancer Therapy Using Antibody-Cytokine Fusion Proteins
KEYNOTE: Cancer Therapy Using Antibody-Cytokine Fusion Proteins
Dari Neri，教授
主旨：用于功能有效载荷选择性靶向的Centryn共轭体
主旨：用于功能有效载荷选择性靶向的Centryn共轭体
纳德勒, Vice President of Research, Aro Biotherapeutics
寡核苷酸疗法：抗体结合物靶向治疗
寡核苷酸疗法：抗体结合物靶向治疗
Art Levin，CSO，Avidity Biosciences
平衡增加的半衰期和蛋白质支架的大小：从临床前到临床的转化
平衡增加的半衰期和蛋白质支架的大小：从临床前到临床的转化
Frefrik Frejd, CSO, Affibody AB
Antagonistic antibodies and KO mice used to establish a key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis
Antagonistic antibodies and KO mice used to establish a key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis
Itai Benhar，特拉维夫大学抗体工程实验室主任
IN-DEPTH ON-DEMAND CONTENT — WHAT YOU WANT. WHEN YOU WANT IT
随需应变的内容可随时提供，以满足您的需要和时间表。
SBT6050，一种HER2导向的TLR8免疫抑制剂™ 治疗性，是一种有效的人类骨髓细胞激动剂，具有肿瘤局部活性
SBT6050，一种HER2导向的TLR8免疫抑制剂™ 治疗性，是一种有效的人类骨髓细胞激动剂，具有肿瘤局部活性
Sean W. Smith, Senior Director, Chemistry, Silverback Therapeutics
基于位点特异性赖氨酸和半胱氨酸的结合
基于位点特异性赖氨酸和半胱氨酸的结合
Barbara Bernardim, Professor, Cambridge University
转移性胃癌和胰腺癌细胞重编程靶点TRA-1-60的新型抗体药物结合物CM-09
转移性胃癌和胰腺癌细胞重编程靶点TRA-1-60的新型抗体药物结合物CM-09
Michael Schopperle, Chief Executive Officer, CureMeta
展示科学海报
考虑在这个虚拟活动中展示海报，从参与中获得更多价值。与你的同龄人分享你的研究，并从其他海报中学习。许多与会者告诉我们，被选为海报展示有助于促进他们公司批准参加活动的过程。今天使用下面的表格在线提交你的海报摘要。
Deadline: Monday, October 12, 2020
请注意，所有海报演示者必须是主要会议的注册与会者。
Exclusive Whitepaper Downloads
Use of Next Generation Protein Therapeutics Over Traditional Monoclonal Antibodies and Different Approaches
Use of Next Generation Protein Therapeutics Over Traditional Monoclonal Antibodies and Different Approaches
根据BIS Research and Research and Markets的数据，全球生物制剂药物发现市场预计将从2015年的81亿美元增加到2025年的227亿美元（图1）。生物制剂发现增长率预计将快于占主导地位的小分子发现部门。预计到2025年，单克隆抗体将占生物制剂市场的不到一半。下一代蛋白质疗法等工程或重组蛋白质预计将在2025年为市场贡献30亿美元。
The dominance of monoclonal antibodies (mAbs) are due to several factors including their efficacy brought about by their high specificity allowing selective targeting
Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies
Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies
过去十年已经看到实质性的imm的增长unotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.
在2020年下一代峰会上与主要买家联系
无论您是在提升公司形象、推出新产品还是专注于新的业务发展机会，请与我们合作确定定制解决方案，以帮助您实现目标。
联系克里斯汀·肖特：+1 857 504 6685或KSchott@informaconnectls.com
